Saturday 17 October 2026 Export ZVRA’s income statement to Excel — free account

Zevra Therapeutics, Inc.

Zevra Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $106.5 million, up 350.9% from fiscal 2024. In the quarter to June 2026, revenue grew 53.3%, EPS fell 88.7%, free cash flow grew 670.9% and total debt rose 4.07%, each against the same quarter a year earlier.

9.95 0.32 −3.12%

Follow ZVRA

Alert me

Market cap: $609.9M
P/E: 10.5×
Fwd P/E: 10.5×
Dividend yield: —
F-score: 6/9
Altman Z: 0.63
Beneish M: 1.46
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total sells 2.52

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	—	—	4	4	—	—	1	1	—	2	—	1

Insider Ownership 0.89%

Capital & Financial Ratios $m

Market Cap 609.88

Revenue 136.07

Net Income 58.26

Free Cash Flow 33.07

Net Debt (221.57)

Current Ratio 5.17

Debt/Equity 0.00

P/E ratio 10.47

Fwd P/E 10.50

P/S ratio 4.33

P/B ratio 2.70

Past 5Y EPS Growth —

This Y EPS Growth (17.88%)

Next Y EPS Growth (15.57%)

Next Y revenue growth 43.98%

Next 5Y EPS Growth 1.47%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 10.80%

10-year low 10-year high

P/B against its own 10 years 44.38%

10-year low 10-year high

EV/Sales against its own 10 years 6.70%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2023	Powerpack
2022	Powerpack
2021	Powerpack
2020	Powerpack
2019	Powerpack
2017	Powerpack

special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	68	69	191	222
Receivables	17	11	23	22
Inventory	—	2	2	2
Other	—	—	—	—
	87	86	223	251

	2023	2024	2025	Q'26
Payables	28	25	12	14
ST’ Debt	38	—	—	—
Other	7	8	14	13
	74	34	39	49

Compound Annual Growth %

	10y	5y	3y
Sales	—	51.62%	118.82%
Cash Flow	0.00%	0.00%	0.00%
Earnings	0.00%	0.00%	0.00%
Book Value	0.00%	0.00%	27.21%

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	36	40	—	—	—
’25	20	26	26	34	106
’24	3	4	4	12	24
’23	3	8	3	13	27
’22	4	1	3	2	10
’21	12	12	2	3	29
’20	2	7	2	2	13

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	6	17	—	—	—
’25	(8)	(4)	5	6	(2)
’24	(16)	(19)	(18)	(16)	(70)
’23	(4)	(9)	(5)	(16)	(34)
’22	(4)	(4)	(7)	(4)	(19)
’21	(3)	17	(3)	(1)	10
’20	(2)	2	(1)	(1)	(2)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	50	22	—	—	—
’25	(8)	(4)	5	5	(2)
’24	(16)	(19)	(18)	(16)	(70)
’23	(4)	(9)	(5)	(16)	(34)
’22	(4)	(4)	(7)	(4)	(19)
’21	(3)	17	(3)	(1)	10
’20	(2)	2	(1)	(1)	(2)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	0.60	0.14	—	—	—
’25	(0.06)	1.21	(0.01)	0.19	1.35
’24	(0.40)	(0.48)	(0.69)	(0.67)	(2.28)
’23	(0.34)	(0.08)	(0.30)	(0.54)	(1.30)
’22	(0.05)	(0.70)	(0.19)	0.17	(0.78)
’21	(2.49)	(0.40)	(0.06)	0.09	(2.11)
’20	(1.92)	0.16	(0.64)	(0.83)	(3.21)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	46.40	39.20	27.44	4.24	1.94	5.08	4.00	3.89	4.20	6.19	Analyst estimates 2026–2028 Powerpack
	High	316.00	86.40	134.40	45.60	22.08	18.15	9.43	6.68	9.76	13.16
People
People	Employees	32	32	33	22	22	24	36	69	59	61
	Revenue/emp, $m	0.00	0.00	0.00	0.58	0.60	1.19	0.28	0.40	0.40	1.75
Income, $m
Income, $m	Revenue	—	—	—	13	13	29	10	27	24	106
	Gross margin, %	0.00	0.00	0.00	77.06	90.18	92.81	97.82	92.09	68.59	84.52
	EBT	(17)	(43)	(57)	(25)	(13)	(9)	(27)	(46)	(90)	87
	EBT margin, %	0.00	0.00	0.00	(191.17)	(96.28)	(29.74)	(263.80)	(167.69)	(381.76)	81.41
	Net income	(17)	(43)	(56)	(25)	(13)	(9)	(27)	(46)	(106)	83
	Depreciation	2	2	2	2	3	0	1	1	5	60
Per share, $
Per share, $	Revenue	0.00	0.00	0.00	6.93	3.34	0.96	0.29	0.77	0.51	1.92
	Earnings	(18.08)	(47.36)	(50.40)	(13.28)	(3.21)	(2.11)	(0.78)	(1.30)	(2.28)	1.40
	Cash flow	(32.63)	(36.14)	(48.37)	(12.81)	(0.49)	0.35	(0.54)	(0.95)	(1.51)	(0.03)
	Capex	(0.70)	(0.20)	(0.02)	(0.01)	(0.01)	0.00	0.00	(0.01)	0.00	(0.01)
	Free cash flow	(33.34)	(36.34)	(48.39)	(12.82)	(0.50)	0.35	(0.55)	(0.95)	(1.51)	(0.04)
	Book value	(20.49)	(62.80)	(59.40)	(40.18)	(16.68)	4.27	2.18	1.75	0.86	2.80
	Shares, m	1	1	1	2	4	30	34	35	46	55
Valuation, ×
Valuation, ×	P/E	—	—	—	0.00	0.00	0.00	0.00	0.00	0.00	6.54
	P/S	—	—	—	0.00	3.36	9.05	15.38	8.82	16.34	4.65
	P/B	—	—	—	0.00	0.00	2.04	2.08	3.91	9.72	3.20
	EV/Sales	—	—	—	0.00	8.18	5.18	8.53	7.91	17.51	3.80
	EV/FCF	—	—	—	(3.60)	(55.12)	14.40	(4.61)	(6.42)	(5.91)	(203.63)
Cash, $m
Cash, $m	Operating cash flow	(30)	(33)	(54)	(24)	(2)	10	(19)	(34)	(70)	(2)
	Capex	(1)	0	0	0	0	0	0	0	—	0
	Free cash flow	(30)	(33)	(54)	(24)	(2)	10	(19)	(34)	(70)	(2)
Balance, $m
Balance, $m	Working capital	68	34	12	2	1	111	81	13	52	184
	Total debt	92	93	82	78	68	2	13	43	60	62
	Net debt	23	51	60	74	64	(111)	(70)	(25)	(10)	(129)
	Shareholders’ equity	(19)	(58)	(67)	(74)	(66)	127	75	62	40	155
Returns, %
Returns, %	ROA	(23.68)	(63.18)	(142.59)	(131.65)	(117.52)	(87.27)	(21.57)	(32.02)	(60.21)	33.52
	ROIC	(529.65)	0.00	0.00	0.00	0.00	29.49	(478.56)	(84.03)	(183.25)	(153.83)
	ROE	114.63	113.86	91.01	34.78	18.12	(207.22)	(26.48)	(67.23)	(207.84)	79.85

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
WVE WAVE Life Sciences Ltd.	$628.6M	— (loss-making)	— (loss-making)	−73.88% (below 0%: shrinking)	n/m	−17.59% (below 0%: shrinking)	100.00%	(3,248.33%)	Compare
CLYM Climb Bio, Inc.	$626.6M	— (loss-making)	—	—	n/m	+3.73% (above 0%: growing)	—	0.00%	Compare
NVCT Nuvectis Pharma, Inc.	$618.0M	— (loss-making)	—	—	n/m	−34.57% (below 0%: shrinking)	—	0.00%	Compare
SLDB Solid Biosciences Inc.	$615.5M	— (loss-making)	— (loss-making)	−100.00% (below 0%: shrinking)	n/m	−39.56% (below 0%: shrinking)	0.00%	0.00%	Compare
ZVRA Zevra Therapeutics, Inc.	$609.9M	10.5×	10.5×	+53.25% (above 0%: growing)	−88.71% (below 0%: shrinking)	+670.87% (above 0%: growing)	96.16%	42.30%
PHAT Phathom Pharmaceuticals, Inc.	$606.8M	— (loss-making)	— (loss-making)	+88.02% (above 0%: growing)	n/m	+96.86% (above 0%: growing)	79.68%	(5.34%)	Compare
OLMA Olema Pharmaceuticals, Inc.	$601.1M	— (loss-making)	—	—	n/m	−54.33% (below 0%: shrinking)	0.00%	0.00%	Compare
CRMD CorMedix Inc	$581.5M	3.0×	16.5×	+156.52% (above 0%: growing)	+13.79% (above 0%: growing)	+185.90% (above 0%: growing)	75.66%	42.10%	Compare
SLN Silence Therapeutics PLC Sponsored ADR	$581.1M	— (loss-making)	— (loss-making)	+197.18% (above 0%: growing)	n/m	+106.95% (above 0%: growing)	97.39%	0.00%	Compare
Median of peers	$611.1M	—	—	+88.02%	—	−6.93%	77.67%	0.00%

All 614 Biotechnology stocks →

Zevra Therapeutics, Inc. (ZVRA) key facts

Strength: Zevra Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $106.5 million, up 350.9% from fiscal 2024.
Zevra Therapeutics, Inc. (ZVRA) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
As of October 16, 2026, ZVRA traded at $9.95, a market capitalization of $609.9 million.
Return on equity was 79.9% and debt-to-equity 0.00.
Its Piotroski F-score is 6 out of 9 and its Altman Z-score is 0.63 (distress zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.